CareDx, Inc.
AI Valuation
AI-generated fair value estimate for this company.
AI Fair Value
$52.53
Market Price
$70.16
Overvalued By
33.6%
Method: 10-year unlevered FCF DCF: $85M normalized FCF base (TTM $84.71M); 12% annual FCF growth yrs 1-5; 6% yrs 6-10; 9% discount rate; 3% terminal growth; -$354.39M net cash (net cash position, $373.64M cash vs. $19.25M debt); 51.73M shares outstanding.
Reasoning: CareDx is a profitable, growing transplant-diagnostics leader (AlloSure/AlloMap) with a debt-free balance sheet and accelerating free cash flow (TTM FCF up over 600% YoY), supporting double-digit growth assumptions moderating over the decade and a moderate discount rate reflecting still-elevated reimbursement/competitive risk in molecular diagnostics.